Cogent Biosciences posted a GAAP net loss of USD 96.4 million for Q2 2026, widening from USD 73.5 million a year earlier.
R&D expense rose 13.83% to USD 70.8 million, driven by SUMMIT, PEAK and APEX trial costs, regulatory work and pipeline investment.
G&A expense more than doubled to USD 31.8 million, on higher commercial readiness spending tied to a potential bezuclastinib launch.
Cash, cash equivalents and marketable securities totaled USD 792.3 million at June 30; pro forma cash was USD 865.9 million, funding operations into late 2028.
FDA accepted an NDA with priority review for bezuclastinib in GIST, with a PDUFA date of Nov. 30, 2026; an AdvSM NDA was submitted June 30.
COGT•
